Our Companies

kannalife sciences laboratory

Our Accomplishments

› First with a license to commercialize the ‘507 patent “Cannabinoids as Antioxidants and Neuroprotectants”. Read More.

› Holds exclusive licenses from the NIH to develop cannabinoid-based treatments for hepatic encephalopathy and chronic traumatic encephalopathy.

› Developed a synthetic molecule related to cannabidiol called KLS-13019, which is 50 times more potent and 400 times less toxic than naturally occurring cannabidiol. Read More.

 

Latest Kannalife™ Sciences News

[button size=”medium_rd_bt” radius=”0″ url=”/companies/kannalife/” position=”ta_center” ex_class=”company-of-firsts-btn”]OVERVIEW[/button][button size=”medium_rd_bt” radius=”0″ url=”/kannalife/news-press/” position=”ta_center” ex_class=”company-of-firsts-btn”]NEWS & PRESS[/button][button size=”medium_rd_bt” radius=”0″ url=”/kannalife/leadership/” position=”ta_center” ex_class=”company-of-firsts-btn”]LEADERSHIP[/button][button size=”medium_rd_bt” radius=”0″ url=”/kannalife/brands/” position=”ta_center” ex_class=”company-of-firsts-btn”]AREAS OF FOCUS[/button][button size=”medium_rd_bt” radius=”0″ url=”/kannalife/contact/” position=”ta_center” ex_class=”company-of-firsts-btn”]CONTACT[/button]